



CLINICAL TRIALS OF TEXAS, INC.

Promoting Health Through Research

Curriculum Vitae

Karen Maria Carcamo, MD

7940 Floyd Curl Drive, Suite 700
San Antonio, Texas 78229

7940 Floyd Curl Drive, Suite 900
San Antonio, Texas 78229

EDUCATION

1992-1996 Residency- Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
1992 Doctor of Medicine, University of California at San Francisco, San Francisco, California
1988 Masters of Public Health, University of California at Los Angeles, Los Angeles, California
1985 Bachelors of Arts in Chemistry and Spanish, University of New Mexico, Albuquerque, New Mexico

LICENSE

1996 Texas Medical Board, # K0663
1995 Pennsylvania Medical License, # MD057796L

PROFESSIONAL EXPERIENCE

1999-Present Institute for Women's Health, San Antonio, Texas
1997-1999 Delos River Walk OB/GYN Associates, San Antonio, Texas
1996-1997 MacGregor Medical Association, Houston, Texas

PROFESSIONAL MEMBERSHIPS

American Board of Obstetrics and Gynecology
Diplomat American Board of OB/GYN
Bexar County Medical Society
Fellow of the American College of OB/GYN

HOSPITAL AFFILIATIONS

Baptist Health Systems, San Antonio, Texas

RESEARCH AFFILIATION(S)

2006-Present Investigator, Clinical Trials of Texas, Inc., San Antonio, Texas

RESEARCH EXPERIENCE

2009-Present: A Multi-Center, Randomized, Active Controlled Study To Investigate The Efficacy And Safety Of Intravenous "Study Drug" In Patients With Iron Deficiency Anemia (IDA)

2009-Present: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of "Study Drug" In Subjects With Endometriosis

2008-Present: A Multi-Center, Randomized, Controlled Study To Investigate The Safety And Tolerability Of A Single Dose Of "Study Drug" Vs. Standard Medical Care In Treating Iron Deficiency Anemia In Subjects Who Are Not Dialysis Dependent

2008-Present: A Multicenter, Randomized, Controlled Study To Investigate The Safety And Tolerability Of "Study Drug" Vs. Standard Medical Care In Treating Iron Deficiency Anemia

2008-Present: A Multicenter, Randomized, Double-Blind, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Doses Of "Study Drug" Versus Placebo In Women With Overactive Bladder

2008-2009: A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Uterine Fibroids

2008-2009: Efficacy And Safety Of "Study Drug" In The Treatment Of Moderate To Severe Vaginal Dryness And Vaginal Pain Associated With Sexual Activity, Symptoms Of Vulvar And Vaginal Atrophy (Vva), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral "Study Drug" 60 Mg Daily Dose With Placebo In Postmenopausal Women

2008-2009: A Multi-Center, Placebo Controlled, Safety And Efficacy Study Of "Study Drug" In Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy

2008-2009: A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Endometriosis-Extension Study

2007-2009: A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating The Safety And Efficacy Of "Study Drug" In The Treatment Of Premenopausal Women With Symptomatic Endometriosis

2007-2009: A Multi-Center, Randomized, Controlled Study To Investigate The Safety And Tolerability Of "Study Drug" Vs. Standard Medical Care In Treating Iron Deficiency Anemia In Heavy Uterine Bleeding And Postpartum Patients

2007-2009: An Open Label Study Of The Contraceptive Efficacy Of An Extended Regimen Of "Study Drug" And "Study Drug"

2007-2008: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation Of The Use Of Topically Administered "Study Drug" Versus Placebo In Subjects With Pain Associated With Fibrocystic Breast Disease

2006-2008: Long-Term Safety Of "Study Drug" Oral Daily Dose For The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women Without A Uterus: A 52-Week Open-Label Follow-Up To "Protocol"

2006-2008: Long-Term Safety Of 30 Mg And 60 Mg Oral Daily Doses Of "Study Drug" In The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women With An Intact Uterus: A 40-Week Randomized, Double-Blind, Placebo-Controlled, Follow-Up To "Protocol"

2006-2008: A Randomized, Placebo-Controlled Phase II Study Of Multiple Dosing Regimens Of Intravaginally Administered "Study Drug" Gel For The Treatment Of Cervical High Risk HPV Infection

2006-2008: Efficacy And Safety Of "Study Drug" In The Treatment Of Vulvar And Vaginal Atrophy (VVA) In Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral "Study Drug" 30 Mg And 60 Mg Daily Doses With Placebo

Signature and Date